Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | KEYNOTE-365: pembrolizumab combination therapy for mCRPC

William Berry • 14 Feb 2020
GU Cancers 2020
Genitourinary Cancer Prostate Cancer Abiraterone Docetaxel Enzalutamide Olaparib Pembrolizumab Prednisone
KEYNOTE-365

William Berry, MD, Duke University Medical Center, Durham, NC, discusses the KEYNOTE-365 trial (NCT02861573) which investigated pembrolizumab combinations for the treatment of metastatic castrate-resistant prostate cancer (mCRPC). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

Related Videos

2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals